FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Tuesday

 

Why this MS drug doesn’t work half the time












(Credit: Getty Images)

Researchers say they’ve figured out why a multiple sclerosis drug simply doesn’t work for up to half of patients.

The drug, called interferon-beta, can prevent flare-ups, but has unpleasant side effects and is expensive.

A new study in mice points to biological mechanisms that can lead to a form of MS that doesn’t respond to the drug. Researchers were able to identify new drug candidates that might help MS patients when interferon-beta treatment fails.

The study shows a really clear molecular mechanism that may explain why some people do not respond to interferon-beta treatment,” says Mari Shinohara, an associate professor of immunology at Duke University and a senior author of the study in Nature Neuroscience. “We’ve found what makes a difference in the response.”

In multiple sclerosis, the body’s immune system mistakenly goes on offense against the nervous system, eating away at the protective coating that wraps around neurons’ long, signal-carrying arms. Without this wrapping, neural signals get jammed and don’t always make it where they need to go, resulting in a vast array of neurological symptoms.

Vary from person to person

Researchers are still sorting out the biological mechanisms that lead to the neural damage of MS, making it tricky to find effective treatments. To add to the challenge,  is mounting that the mechanisms could vary from patient to patient, depending on the exact mix of genetic factors and environmental stimuli that led to their disease.

In a 2012 mouse study, Shinohara’s team found that interferon-beta works by inhibiting a giant immune protein complex called the NLRP3 inflammasome. The NLRP3 complex appears to play a key role in triggering the faulty immune responses that make MS patients sick. However, in the same study, they also found that some mice got sick even without this inflammasome—and in these mice, the interferon-beta treatment was completely ineffective.

In the current study, the team wanted to figure out how this second form of the disease was triggered.

We knew the second pathway bypassed the NLRP3 inflammasome,” Shinohara says. “So the question became, what is actually involved?”

They found that two specific receptors, called CXCR2 and LTBR, were central to the development of the disease in the mice who did not respond to interferon-beta. And they found that treating the mice with a molecule that blocks these receptors improved their symptoms.

We found  depending on which type of disease the mice had, we could choose the appropriate treatment,” Shinohara says.

Pain, inconvenience, and cost

To see if the CXCR2 and LTBR receptors might also play a role in human MS, the team used data gathered as a part of the Murdock-MS study in Kannapolis, North Carolina, to compare the genetic profiles of MS patients who responded to interferon-beta treatment with those who didn’t.

We identified individuals who were not responsive to the interferon-beta treatment, and looked at their CXCR2 and LTBR relative gene expression levels,” says Simon Gregory, a professor of medicine and molecular genetics and microbiology at Duke and a  of the paper. “We found them to be up-regulated,” meaning they were producing more of the receptors, he says.

Story Source: The above story is based on materials provided by FUTURITY
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News